Roche Holding, a leading Swiss pharmaceutical company, has announced that during a late-stage clinical trial for a lung-cancer treatment, there was an unintended disclosure of data. However, the study will proceed until a final analysis on overall survival is completed.
The inadvertent disclosure occurred during the second interim analysis of the phase 3 trial, as the results for the overall survival rate were not fully matured. Despite this incident, the trial will continue as planned, with both patients and investigators remaining blinded to the ongoing study.
Roche’s trial focuses on evaluating the effectiveness of the immunotherapy drug tiragolumab in combination with Tecentriq, compared to Tecentriq alone. This combination serves as an initial treatment for individuals with advanced or metastatic non-small cell lung cancer.
According to the interim results, patients who received the tiragolumab and Tecentriq combination exhibited an estimated median overall survival of 22.9 months, surpassing the 16.7 months observed in the monotherapy arm. The company also reported that the combination treatment was well tolerated by patients.
It is worth noting that Roche is committed to conducting a thorough analysis of overall survival before finalizing its findings.
